Parallel Advisors LLC boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,458 shares of the medical research company's stock after purchasing an additional 3,114 shares during the period. Parallel Advisors LLC's holdings in Thermo Fisher Scientific were worth $18,142,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the company. Semus Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.0% during the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after buying an additional 18 shares in the last quarter. Evernest Financial Advisors LLC grew its position in Thermo Fisher Scientific by 4.0% in the fourth quarter. Evernest Financial Advisors LLC now owns 521 shares of the medical research company's stock valued at $271,000 after purchasing an additional 20 shares in the last quarter. Proactive Wealth Strategies LLC grew its position in Thermo Fisher Scientific by 2.7% in the fourth quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company's stock valued at $392,000 after purchasing an additional 20 shares in the last quarter. Cassaday & Co Wealth Management LLC grew its position in Thermo Fisher Scientific by 0.9% in the fourth quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company's stock valued at $1,189,000 after purchasing an additional 20 shares in the last quarter. Finally, Callan Capital LLC grew its holdings in shares of Thermo Fisher Scientific by 2.7% in the 4th quarter. Callan Capital LLC now owns 773 shares of the medical research company's stock valued at $402,000 after acquiring an additional 20 shares in the last quarter. Institutional investors own 89.23% of the company's stock.
Analyst Ratings Changes
A number of research analysts have weighed in on the company. Robert W. Baird decreased their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Stifel Nicolaus decreased their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Royal Bank of Canada decreased their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Finally, Citigroup reduced their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average target price of $607.43.
Read Our Latest Stock Report on Thermo Fisher Scientific
Insider Buying and Selling
In related news, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,075 shares of company stock worth $7,305,942 in the last 90 days. Insiders own 0.33% of the company's stock.
Thermo Fisher Scientific Stock Performance
NYSE TMO traded down $1.34 during trading on Friday, reaching $402.41. The company's stock had a trading volume of 2,521,302 shares, compared to its average volume of 1,878,887. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $151.91 billion, a price-to-earnings ratio of 24.34, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88. The firm has a 50 day moving average price of $430.85 and a 200 day moving average price of $500.06.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the prior year, the company posted $5.11 EPS. The company's revenue was up .2% compared to the same quarter last year. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is 10.09%.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
